Veradermics (NYSE:MANE) Director John Childs Sells 100,000 Shares of Stock

Veradermics, Incorporated (NYSE:MANE) Director John Childs sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $107.12, for a total value of $10,712,000.00. Following the completion of the sale, the director directly owned 194,117 shares in the company, valued at approximately $20,793,813.04. This represents a 34.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Veradermics Stock Up 2.0%

Veradermics stock opened at $113.18 on Friday. Veradermics, Incorporated has a 52 week low of $32.00 and a 52 week high of $131.24. The company has a market capitalization of $4.73 billion and a price-to-earnings ratio of -85.74. The business has a 50-day simple moving average of $109.87.

Veradermics (NYSE:MANE) last announced its earnings results on Tuesday, August 11th. The company reported ($0.58) earnings per share for the quarter, meeting the consensus estimate of ($0.58). On average, analysts predict that Veradermics, Incorporated will post -2.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on MANE. UBS Group set a $170.00 price objective on Veradermics in a research report on Wednesday, July 15th. Needham & Company LLC boosted their target price on shares of Veradermics from $136.00 to $164.00 and gave the stock a “buy” rating in a research report on Wednesday, July 15th. Wall Street Zen upgraded shares of Veradermics from a “sell” rating to a “hold” rating in a research note on Saturday, August 1st. B. Riley Financial initiated coverage on shares of Veradermics in a report on Wednesday, July 15th. They issued a “buy” rating and a $170.00 price target for the company. Finally, Citigroup raised their price target on shares of Veradermics from $135.00 to $160.00 and gave the stock a “buy” rating in a research report on Thursday, July 16th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Veradermics presently has an average rating of “Moderate Buy” and an average target price of $153.00.

About Veradermics

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for pattern hair loss, or PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation.